Under the normal situation of Chinese and foreign pharmaceutical enterprises joining hands, the mode of cooperation is becoming more and more diversified

On the afternoon of August 24, Ipsos China ("Ipson") and Baiyang Pharmaceutical Group's Qingdao Baiyang Pharmaceutical Co., Ltd. ("Baiyang") held a signing ceremony in Beijing, and the two sides signed cooperation agreements on Fu Jingqing ® (complex polyglycol electrolyte dispersion (III)), Danakon ® (Ginkgo leaf tablets).
Chinese and foreign pharmaceutical companies join forces to become the norm, the mode of cooperation gradually diversified it is understood that Fu Jingqing as a clear intestine products, by the Original Research group, listed in China in 2004, and has been included in the national health insurance directory.
Danakon, a treatment drug for older patients with cognitive impairment, was originally developed by Ipscom and included in the National Health Insurance Directory in 2000.
According to the agreement, in the cooperation between the two sides, Baiyang will use its professional team and the layout of the whole country to make Fu Jingqing® (complex polyglycol electrolyte dispersion (III)) deeper and broader service primary hospitals, Ipsos will continue to serve the existing market, strong and strong joint efforts to meet China's medical needs in the field of intestinal preparation®
fact, this is not the first time that Ipson has cooperated with Chinese companies, and recently it held a signing ceremony with Shanghai Pharmaceutical Holdings Limited ("Shanghai Pharmaceutical Holdings") at the headquarters of Shanghai Pharmaceutical Holdings.
Ipsos China General Manager Chen Jialin and Li Yongzhong, General Manager of Shanghai Pharmaceutical Holdings Co., Ltd., signed a relevant cooperation agreement on behalf of Fusong (Polyglycol 4000 Scatter) in completely channels, and decided to continue to promote the application of Fusong (Polyglycol 4000 Scatter) in the field and better meet the needs of patients.
fact, in recent years, with the changing pharmaceutical industry, the market is more open, Chinese and foreign pharmaceutical companies frequently strong joint efforts to jointly develop the domestic and international pharmaceutical market trend has become more and more obvious.
addition to Ipson, more and more multinational pharmaceutical companies are working with domestic pharmaceutical companies to open up the domestic market.
, on August 17th Bayer announced a strategic partnership with innovative drug research and development company Huali Pharmaceuticals to reach a commercial cooperation agreement in China on the new diabetes treatment drug dorzagliatin.
that the agreement will take advantage of Bayer's strengths in the field of diabetes management in China and the innovative capabilities of Hua-Li Pharmaceuticals to provide new treatment options for diabetic patients in China.
July 15th, Novartic and Nod and China Resources Pharmaceuticals also announced that, based on the earlier letter of intent signed by the two sides, Novartic and Nord and China Resources Pharmaceuticals' China Resources 39 Pharmaceutical Co., Ltd. will jointly promote the recombinant human growth hormone injection Noze ® Chinese mainland through a contract sales model.
From the above, we can see that after years of development, China's integration with the world accelerated, the importance of china's pharmaceutical market has been constantly discovered, the cooperation between multinational pharmaceutical companies and local pharmaceutical companies is becoming more frequent, while the mode of cooperation is more diversified.
this trend, the industry believes that in the future in product promotion, channel development, product distribution and other aspects, multinational pharmaceutical companies and local pharmaceutical companies will have more "one shot at a time."